Mar 2, 2022 · A recent meta-analysis showed that elevated MDSCs are associated with an increased risk for disease progression and worse prognosis of HCC [57]. Targeting MDSCs may promote anti-tumor treatments, and several MDSC-targeting approaches are being tested in cancer patients (Table 1).

Dec 14, 2016 · We showed that MDSCs express surface programmed death ligand 1 (PD-L1) molecules in peripheral blood mononuclear cells (PBMCs) and tumor infiltrating lymphocyte (TILs) from HCC patients.

May 14, 2021 · Our data indicated that monocytic MDSCs were mobilized and recruited to liver graft during acute phase injury, and to promote HCC recurrence after transplantation. Targeting MDSC mobilization...

Mar 27, 2025 · To some extent, it is still necessary to evaluate their immunosuppressive functions to accurately determine the cell type. Although recent advances in emerging technologies, such as single-cell sequencing and spatial transcriptomics, have contributed to progress in MDSC biomarker research, studies on MDSC biomarkers in HCC remain relatively ...

Nov 2, 2020 · Here, we report an elevation of MDSCs in the peripheral blood of patients with other hepatobiliary malignancies including non-viral HCC, neuroendocrine tumors (NET), and colorectal carcinoma with liver metastases (CRLM), but not cholangiocarcinoma (CCA).

Sep 11, 2017 · Using hepatocellular carcinoma (HCC) as a cancer model, we show that hypoxia, through stabilization of hypoxia-inducible factor-1 (HIF-1), induces ectoenzyme, ectonucleoside triphosphate...

May 7, 2019 · Systemic therapy for advanced hepatocellular carcinoma (HCC) has been focusing on overcoming tumor angiogenesis and immunosuppression. Myeloid-derived suppressor cells (MDSCs) promote both angiogenesis and immunosuppression in …

Apr 1, 2023 · Approach and results: By immunohistochemistry and multiplex immunofluorescence (mIF) staining, we showed that METTL1 expression was enhanced in post-RFA recurrent HCC, accompanied by increased CD11b + CD15 + polymorphonuclear-myeloid-derived suppressor cells (PMN-MDSCs) and decreased CD8 + T cells.

In line with studies in most epithelial cancers, MDSCs accumulate in the blood and tumours of patients with hepatocellular carcinoma (HCC) [2–4]. Up to now, the func-tional role of MDSCs in development and progression of hepato-cellular carcinoma has still to be defined.

Myeloid derived suppressor cells (MDSC) are immature myeloid cells with immunosuppressive activity. They accumulate in tumor-bearing mice and humans with different types of cancer, including hepatocellular carcinoma (HCC).